WO2006106970A1 - 3重螺旋構造を有するタンパク質の製造方法 - Google Patents
3重螺旋構造を有するタンパク質の製造方法 Download PDFInfo
- Publication number
- WO2006106970A1 WO2006106970A1 PCT/JP2006/306941 JP2006306941W WO2006106970A1 WO 2006106970 A1 WO2006106970 A1 WO 2006106970A1 JP 2006306941 W JP2006306941 W JP 2006306941W WO 2006106970 A1 WO2006106970 A1 WO 2006106970A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- collagen
- human
- dna
- type
- protein
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 title claims abstract description 51
- 102000004169 proteins and genes Human genes 0.000 title claims description 39
- 238000004519 manufacturing process Methods 0.000 title claims description 33
- 108010035532 Collagen Proteins 0.000 claims abstract description 168
- 102000008186 Collagen Human genes 0.000 claims abstract description 160
- 229920001436 collagen Polymers 0.000 claims abstract description 158
- 210000004027 cell Anatomy 0.000 claims abstract description 74
- 239000013598 vector Substances 0.000 claims abstract description 26
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 23
- 239000012228 culture supernatant Substances 0.000 claims description 68
- 102000000503 Collagen Type II Human genes 0.000 claims description 41
- 108010041390 Collagen Type II Proteins 0.000 claims description 41
- 102000001187 Collagen Type III Human genes 0.000 claims description 37
- 108010069502 Collagen Type III Proteins 0.000 claims description 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 238000012258 culturing Methods 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 238000012546 transfer Methods 0.000 claims description 10
- 238000009395 breeding Methods 0.000 claims description 3
- 230000001488 breeding effect Effects 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 claims description 2
- 210000003292 kidney cell Anatomy 0.000 claims description 2
- 238000011109 contamination Methods 0.000 abstract description 4
- 108020004414 DNA Proteins 0.000 description 53
- 108010022452 Collagen Type I Proteins 0.000 description 51
- 102000012422 Collagen Type I Human genes 0.000 description 51
- 239000002609 medium Substances 0.000 description 34
- 102000057297 Pepsin A Human genes 0.000 description 33
- 108090000284 Pepsin A Proteins 0.000 description 33
- 229940111202 pepsin Drugs 0.000 description 33
- 239000002299 complementary DNA Substances 0.000 description 29
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 27
- 239000013604 expression vector Substances 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 22
- 239000000499 gel Substances 0.000 description 22
- 229920002401 polyacrylamide Polymers 0.000 description 22
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 18
- 241000588724 Escherichia coli Species 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 14
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 12
- 230000037319 collagen production Effects 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 239000007857 degradation product Substances 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 229910002092 carbon dioxide Inorganic materials 0.000 description 9
- 229940096422 collagen type i Drugs 0.000 description 9
- 230000004544 DNA amplification Effects 0.000 description 8
- 239000006142 Luria-Bertani Agar Substances 0.000 description 8
- 229960000723 ampicillin Drugs 0.000 description 8
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
- 239000001569 carbon dioxide Substances 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000012620 biological material Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 5
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 108020001096 dihydrofolate reductase Proteins 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 235000005956 Cosmos caudatus Nutrition 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 108010051696 Growth Hormone Proteins 0.000 description 4
- 241001483952 Peach chlorotic mottle virus Species 0.000 description 4
- 102100038803 Somatotropin Human genes 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000013599 cloning vector Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000012192 staining solution Substances 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 108010045569 atelocollagen Proteins 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 240000003291 Armoracia rusticana Species 0.000 description 2
- 235000011330 Armoracia rusticana Nutrition 0.000 description 2
- 102000004266 Collagen Type IV Human genes 0.000 description 2
- 108010042086 Collagen Type IV Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000004405 Collectins Human genes 0.000 description 2
- 108090000909 Collectins Proteins 0.000 description 2
- 241000510032 Ellipsaria lineolata Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000193764 Brevibacillus brevis Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003367 anti-collagen effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Definitions
- the present invention relates to a method for producing a protein having a triple helical structure. More specifically, the present invention relates to a method for producing human 'collagen or a partial peptide of human' collagen.
- An object of the present invention is to provide a partial peptide of human 'collagen and human' collagen which is safe for a living body and easy to obtain and a method for producing the same.
- the present invention relates to human 'collagen and human ⁇ by stable transduction of mammalian expression vectors obtained by inserting human' collagen cDNA into Chiyazuno, Muster ovary (CHO) cells. It is in providing the manufacturing method of the partial peptide of collagen.
- Collagen is a protein distributed in almost all tissues of the body, including skin 'bone' cartilage, and plays an important role such as maintaining the structure of tissues' organs as a scaffold for cells. Is well known.
- collagen is a bioabsorbable material that is decomposed by collagenase secreted from fibroblasts and collagenase present in phagocytes. In this way, collagen is considered to be useful as a biological material because it is biocompatible and is a bioabsorbable material. So far, collagen has been used as a covering material for skin damage sites as a biological material, and healing improvements have been reported (Non-patent Documents 1 and 2).
- Non-Patent Document 1 Surg. Forum, 10, 303 (1960)
- Non-Patent Document 2 J. Surg. Res., 10, 485-491 (1970)
- Non-Patent Document 3 Lancet, 342, 799 (1993)
- Non-Patent Document 4 Science, 261, 1727-1730 (1993)
- Patent Document 1 JP-A-10-179169
- collagen is a useful material as a biological material or medicine for regenerative medicine and living transplantation.
- Conventionally used collagen is derived from tissues of large animals other than humans such as butterfly. is there.
- Collagen is originally a protein with low immunogenicity, but it has been reported that when a heterogeneous animal's collagen is transplanted, implanted or administered into a human body as a biological material, an immune reaction is induced with a low frequency. (J. Im munol, 136, 877-882 (1986), Biomaterials, 11, 176-180 (1990)).
- the use of collagen derived from ushi has become impossible due to the problem of prion contamination in ushi.
- yeast Japanese Patent Publication No. 7-501939
- insect cells Japanese Patent Laid-Open No. 8-2397
- the present inventors are able to highly express a foreign gene using, as a host, a cell with a low expression level of collagen molecules among various mammalian cells.
- the host By introducing the collagen gene construct into the vector, the host The present inventors have found that human 'collagen can be produced in large quantities with almost no cell-derived collagen mixed therein, and have completed the present invention.
- Such a collagen production method has not been reported so far when a large amount of the introduced collagen gene is expressed and human collagen is preferentially produced in a host cell.
- the present inventors have developed a vector capable of highly expressing a foreign gene using a mammal having a low expression level of collagen, which is one of proteins having a triple helical structure, as a host.
- a construct obtained by introducing a collagen gene we have succeeded in developing a large-scale production method for human'collagen without requiring a complicated purification process, thereby completing the present invention.
- the present invention provides the following [1] to [15].
- a method for producing a protein having a triple helical structure comprising the following steps (a)
- the DNA force is at least one DNA selected from the DNA cartridges described in (a) or (b) below.
- [12] Human 'collagen produced according to the method of any one of [1] to [11].
- [13] A vector into which at least one DNA selected from the DNAs described in (a) or (b) below is introduced.
- a kit for producing a protein having a triple helical structure comprising the vector according to [13] or the mammalian cell according to [14].
- FIG. 1 is a diagram showing a human type I a 1 chain collagen expression construct.
- HColIal H-type ⁇ 1 chain collagen cDNA
- PCMV Cytomegalovirus promoter
- BGHPA Cushion signal with GH growth hormone gene poly A
- PSVd Simian virus 40 promoter without enhancer
- DHFR Mouse Dihydrofolate reductase cDNA
- SVpA Simian virus 40 poly A addition signal
- ColElori Origin of replication in E. coli
- Neor Selectable marker in mammalian cells (G418 resistance) and Selective marker in E. coli (kanamycin resistance) ).
- FIG. 2 is a diagram showing a human type I ⁇ 2-chain collagen expression construct.
- HColIa2 H-type ⁇ 2 chain collagen cDNA
- PCMV Cytomegalovirus promoter
- BGHPA Cushion signal with ushi growth hormone gene poly A
- PSVd Simian virus 40 promoter without enhancer
- DHFR Mouse Dihydrofolate reductase cDNA
- SVpA Simian Viral 40 poly A addition signal
- ColElori origin of replication in E. coli
- Neor selection marker in mammalian cells (G418 resistance) and selection marker in E. coli (kanamycin resistance).
- FIG. 3 is a diagram showing a human type II ⁇ 1 chain collagen expression construct.
- HColIIal human type II a 1-chain collagen cDNA
- PCMV cytomegalovirus promoter
- BGHPA moss growth hormone gene poly
- PSVd simian virus 40 promoter without enhancer
- DHFR Mouse dihydrofolate reductase cDNA
- SVpA Simian virus 40 poly
- ColElori Origin of replication in E. coli
- Neor Selectable marker in mammalian cells (G418 resistance) and Selective marker in E. coli ( (Kanamycin resistance).
- FIG. 4 is a diagram showing a human type III ⁇ 1 chain collagen expression construct.
- HColIIIal Human type III a 1 chain collagen cDNA
- PCMV Cytomegalovirus promoter
- BGHPA Cushion signal with ushi growth hormone gene poly A
- PSVd Simian virus 40 promoter without enhancer
- DHFR Mouse dihydrofolate reductase cDNA
- SVpA simian virus 40 poly A addition signal
- ColElori origin of replication in E. coli
- Neor selectable marker in mammalian cells (G418 resistance) and selectable marker in E. coli ( (Kanamycin resistance).
- FIG. 5 is a photograph showing analysis of recombinant human collagen type I in culture supernatant by SDS-polyacrylamide gel electrophoresis. Lane 1: Human type I collagen (100 g / mL), Lane 2: Recombinant type I collagen.
- FIG. 6 is a photograph showing analysis by SDS-polyacrylamide gel electrophoresis of pepsin degradation products of thread-replaceable human type I collagen in the culture supernatant.
- Lane 1 Recombinant human type I collagen (185 g / mL)
- Lane 2 Recombinant type I collagen (20-fold concentrated).
- FIG. 7 is a photograph showing detection of purified recombinant human type I collagen and its pepsin degradation product by Western plotting.
- FIG. 8 is a photograph showing analysis by SDS-polyacrylamide gel electrophoresis of recombinant human type II collagen in the culture supernatant.
- Lane 1 human type II collagen (100 g / mL)
- lane 2 recombinant type II collagen.
- FIG. 9 is a photograph showing analysis by Western blotting of recombinant human type II collagen in the culture supernatant.
- Lane 1 human type II collagen (10 g / mL)
- lane 2 recombinant type II collagen (diluted 10-fold).
- FIG. 10 is a photograph showing analysis by SDS-polyacrylamide gel electrophoresis of pepsin degradation products of thread-replaceable human type II collagen in the culture supernatant.
- Lane 1 Human type II collagen (100 g / mL)
- Lane 2 Recombinant type II collagen (5-fold concentrated).
- FIG. 11 is a photograph showing an analysis by Western blotting of a pepsin degradation product of recombinant human type II collagen in the culture supernatant.
- Lane 1 human wrinkle type collagen (10 g / mL)
- lane 2 thread changeable type II collagen.
- FIG. 12 is a photograph showing analysis of recombinant human type III collagen in the culture supernatant by SDS-polyacrylamide gel electrophoresis. Lane 1: Human type III collagen (100 g / mL), Lane 2: Recombinant type III collagen.
- FIG. 13 is a photograph showing an analysis by Western blotting of recombinant human type III collagen and its pepsin degradation product in the culture supernatant.
- Lane 1 human type III collagen (10 g / mL)
- lane 2 recombinant type III collagen (10-fold dilution)
- lane 3 recombinant type III collagen pepsin degradation product.
- FIG. 14 is a photograph showing analysis of purified recombinant human type III collagen in culture supernatant by SDS-polyacrylamide gel electrophoresis.
- the present invention relates to a protein having a triple helical structure comprising the following steps (a) to (c): It relates to a manufacturing method.
- the "protein having a triple helix structure" of the present invention is not particularly limited as long as it has a triple helix structure, preferably collagen or collectin, more preferably collagen.
- a protein having a triple helix structure may be a protein in which a triple helix is constructed in the culture production stage, or a protein having a triple helix structure formed by purification or the like after the culture production. Also good.
- a force that is a protein capable of forming a triple helical structure may be produced in a large amount in the state of a single-stranded structure.
- the origin of the collagen of the present invention is not particularly limited, and preferred examples include collagen derived from mammals, and more preferably derived from humans.
- the collagen of the present invention includes those obtained by modifying a part of the amino sequence of collagen by substitution or deletion, and those having an amino acid sequence not derived from collagen.
- a method for obtaining a transduced cell obtained by introducing a vector into a host mammalian cell and expressing a protein molecule is known, and the same method can be applied to the present invention.
- Collagen is synthesized as a recombinant protein in a cell into which the above foreign gene high expression vector has been introduced, and can be examined as follows. I.e. Using a commercially available antibody that specifically binds to human collagen, it can be confirmed to be a collagen peptide by an immunochemical method such as Western blotting. Usually, collagen is not migrated according to the molecular weight in SDS polyacrylamide gel electrophoresis (Nature, 227, 680-685 (1970)), and therefore, after electrophoresis with collagen as a marker, the method of Matsudaira et al. (J.
- Biol Chem., 261, 10035-10038 (1987)) can be transferred to a nylon membrane or a -trocellulose membrane, and the reactivity with an anti-collagen antibody can be investigated. Furthermore, the presence of a molecule having a triple helical structure in the recombinant collagen product produced by the expression vector can be examined as follows.
- Normal fibrous collagen is a triple-stranded molecule formed from three subunits (a chain), and has a triple helical structure in the molecule.
- Collagen having a triple helical structure is known to be resistant to pepsin digestion. Therefore, the protein supernatant was digested with pepsin under acidic conditions and examined for its pepsin-resistant structure by examining the culture supernatant of the cells into which the above foreign gene high expression vector was introduced. Can be shown to exist.
- the expression vector of the present invention has the same characteristics as those found in vivo in host cells, that is, the ability to synthesize pepsin-resistant collagen.
- Mammalian cells used for culturing as host cells in the present invention are not particularly limited, but preferred examples include CHO cells and HEK293 cells.
- the CHO cells or HEK293 cells used in the present invention can be cultured in a large amount by suspension culture.
- weakened neomycin phosphate transferase gene, mouse dihydrofolate reductase gene, human 'collagen or partial peptide of human' collagen 1 x 10 8 to 1 x 10 9 recombinant CHO cells obtained by transduction with a human collagen expression vector that has both the cDNA to be loaded in a shaker flask or spinner flask in 100 mL to lL culture medium Can be cultured. After culturing this for an appropriate time, the culture supernatant can be collected to extract a large amount of protein.
- a human collagen expression vector having both a weakened neomycin phosphotransferase gene, a mouse dihydrofolate reductase gene, human collagen or a cDNA encoding a partial peptide of human collagen In the CHO cell culture supernatant, there is also a strong collagen that forms a normal triple chain molecule at the same time as a triple chain collagen molecule having a triple helix structure.
- collagen molecules that do not have a triple helix structure are digested by pepsin. Therefore, collagen molecules that do not have a triple helix structure can be decomposed and removed by pepsin.
- proteins in the culture supernatant other than collagen can also be decomposed and removed.
- a human 'collagen expression vector having a weak neomycin phosphate transferase gene, a mouse dihydrofolate reductase gene, and a cDNA encoding a human' collagen or a partial peptide of human 'collagen can be transformed. All the proteins present in the culture supernatant of the recombinant CHO cells obtained by the introduction can be directly treated with pepsin to decompose and remove non-collagenous proteins, as well as to decompose and remove collagen that does not have a triple helix structure. it can.
- Human 'collagen to be used in the present invention is currently known! / All human' collagens including types I to XXI collagen, and partial peptides of these collagens are also included. Include.
- the type of collagen of the present invention is not particularly limited, but representative examples include type I, type II, type III, type IV, type V, type VII, type IX, type XI, type XII, type XVII, or type XVIII. This includes, for example, type I, type II, type III.
- Types I, IV, V, IX, and XI each consist of two or three types of ⁇ chain, and types II, III, VII, XII, XVII, and XVIII each consist of one type of ⁇ chain. These are:-. I a l (I)] o; 20), Type II: [H 1 (11)]
- the molecular structure of bright collagen is not particularly limited.
- the molecular structure of the collagen of the present invention is not limited to the molecular structure derived from natural collagen, and three kinds of ⁇ chains different from the above may be artificially combined.
- the nucleotide sequence of the DNA encoding the a 1 chain of type I collagen of the present invention is shown in SEQ ID NO: 1, and the nucleotide sequence of the DNA encoding type I collagen (X2 chain is expressed in SEQ ID NO: 4; II
- the base sequence of the DNA encoding the type 1 collagen a 1 chain is shown in SEQ ID NO: 7, and the base sequence of the DNA encoding the type III collagen a 1 chain is shown in SEQ ID NO: 10.
- the DNA encoding the collagen of the present invention is preferably an oligonucleotide having a base sequence ability described in any one of SEQ ID NOs: 1, 4, 7, and 10, preferably SEQ ID NOs: 1, 4, 7,
- the oligonucleotide having a base sequence ability described in any one of 10 may include an oligonucleotide that selectively hybridizes. Selectively hybridizing is a properly stringent hybridizer when present in a sample of DNA or RNA that has a pre-determined sequence (ie, a second polypeptide). Nucleic acid molecules that hybridize, become double-stranded, or bind only essentially to each other under the conditions of Chillon.
- the stringent conditions are, for example, usually 42 ° C, 2 ⁇ SSC, 0.1% SDS, preferably 50 ° C, 2 ⁇ SSC, 0.1% SDS, and more preferably 65 ° C. .
- Forces that are conditions of C, 0.1 X SSC and 0.1% SDS There are no particular restrictions on these conditions. Multiple factors such as temperature and salt concentration can be considered as factors affecting the stringency of a hybridization, and those skilled in the art will realize the optimal stringency by selecting these factors as appropriate. Is possible.
- the collagen produced may be in the form of a procollagen molecule in which a propeptide is bonded to the N-terminus and C-terminus, or in a state in which the propeptide is removed. There may be.
- partial peptide of collagen means a polypeptide encoded by a polynucleotide of 20% or more (eg, 20, 30, 40, 50, 60, 70, 80, 90%) of cDNA encoding collagen. Say. Also included are those obtained by modifying a part of the amino acid sequence of these collagens and those having a non-collagen amino acid sequence added.
- mammalian cells with a small amount of collagen expression means 1 X 10 6 cells Z Examples of cells having a collagen production amount of 50 ngZmL or less when cultured in mL are preferable !, CHO, and more preferably CHO cells and HEK293 cells.
- “high expression” means collagen expression of 10 gZmL or more, preferably collagen expression of 50 ⁇ gZmL or more.
- a vector capable of highly expressing a foreign gene means, for example, a mammalian cell chromosome because the function of a drug selection marker gene in a mammalian cell contained in the vector is weak.
- the pNOWZCMV-AA vector can be mentioned as a vector characterized by being selectively inserted into the above active region of transcription.
- the pNOWZCMV-AA vector is known from JP-A-10-179169.
- the culture method may be either floating or adherent culture.
- the gene for human type I ⁇ 1 chain collagen has already been cloned and its nucleotide sequence has been reported (EMBL gene database registration name ⁇ 000088) ⁇ The sequence is shown in SEQ ID NO: 1.
- Human type I alcDNA was amplified from human testis-derived cDNA by the polymerase 'chain' reaction (PCR) method ("PCR Technology", published by Stockton Press (1989)). In other words, the human testis-derived cDNA (Betaton's Dickinson) is used as the cocoon type and SEQ ID NO: 2.
- the full length sequence of SEQ ID NO: 1 was amplified by PCR as a lymer. That is, using a commercially available PCR amplification kit (TaKaRa LA Taq with GC Buffer: Takara Bio Inc.), After heat treatment for 5 minutes, three steps of denaturation (94 ° C, 20 seconds), primer annealing (60 ° C, 30 seconds), amplification (72 ° C, 3 minutes 30 seconds) are repeated 35 times, and then 72 ° C. The reaction was completed after 7 minutes of treatment. Thereafter, all PCR reactions described in this example were carried out in the same reaction cycle.
- PCR products were separated by agarose gel electrophoresis and ligated using a PCR product cloning vector (pT7Blue kits: Novagen) and a ligation kit (DNA ligation kit ver. 2: Takarabio).
- a PCR product cloning vector pT7Blue kits: Novagen
- a ligation kit DNA ligation kit ver. 2: Takarabio
- plasmid DNA was obtained by culturing a colony having ampicillin-resistant properties that appeared on LB agar medium (Difco).
- a DNA fragment encoding human type I a 1-chain collagen excised from this plasmid DNA and the foreign gene high expression vector pNOWZCMV—AA Not I and Xba I digestion product prepared in Example 1 was used as a DNA ligation kit ver.2.
- Plasmid DNA (pNOW-hColIal, Fig. 1) was obtained by culturing one colony with ampicillin-resistant properties that appeared on LB agar medium after introducing DNA linked to E. coli XL-I Blue strain. .
- the full length sequence of SEQ ID NO: 4 was amplified by PCR.
- the obtained PCR products were separated by agarose gel electrophoresis and ligated using a PCR product cloning vector (pT7Blue kits: Novagen) and a ligation kit (DNA ligation kit ver.2: Takara Bio Inc.).
- a PCR product cloning vector pT7Blue kits: Novagen
- DNA ligation kit ver.2 Takara Bio Inc.
- plasmid DNA was obtained by culturing 4 colonies having ampicillin resistant properties that appeared on LB agar medium (Difco). Using a DNA ligation kit ver.
- the gene for human type II a 1 chain collagen has already been cloned and its nucleotide sequence has been reported (EMBL gene database registration name NM 001844.1) o The sequence is shown in SEQ ID NO: 7.
- Human type II ⁇ lcDNA was amplified by PCR from cDNA derived from human testis. That is, human testis-derived cDNA (Betaton's Dickinson) is used as a saddle type and SEQ ID NO: 8
- the full-length sequence of SEQ ID NO: 7 was amplified by PCR.
- the obtained PCR products are separated by agarose gel electrophoresis and ligated using a PCR product cloning vector (pT7Blue kits: Novagen) and a ligation kit (DNA ligation kit ver.2: Takara Bio Inc.). It was.
- pT7Blue kits Novagen
- DNA ligation kit ver.2 Takara Bio Inc.
- plasmid DNA was obtained by culturing 4 colonies with ampicillin-resistant properties that appeared on LB agar medium (Difco). DNA fragment encoding human type II ⁇ 1 chain collagen excised from this plasmid DNA and foreign gene high expression vector pNOWZCMV—V Not I and Xba
- Plasmid DNA (pNOW-hColIIal, Fig. 3) was obtained by culturing one colony with ampicillin-resistant properties that appeared on LB agar after introducing DNA linked to E. coli XL-I Blue strain.
- human type III a 1 chain collagen has already been cloned and its nucleotide sequence has been reported (EMBL gene database registration name X14420). The sequence is shown in SEQ ID NO: 10.
- Human type III ⁇ lcDNA was amplified by PCR from cDNA derived from human liver. In other words, human liver-derived cDNA (Wako Pure Chemical Industries) is used as a cage type and the oligonucleotide of SEQ ID NO: 11 is used.
- the full-length sequence of SEQ ID NO: 10 was amplified by PCR. Obtain the PCR product They were separated by galose gel electrophoresis and ligated using a PCR product cloning vector (pT7Blue kits: Novagen) and a ligation kit (DNA ligation kit ver. 2: Takara Bio Inc.). After introducing DNA linked to E. coli XL-I Blue strain, plasmid DNA was obtained by culturing 4 colonies having ampicillin resistance property that appeared on LB agar medium (Difco).
- Plasmid DNA (pNOW-hColIIIal, Fig. 4) was obtained by culturing one colony with ampicillin resistance that appeared on the LB agar medium after introducing DNA linked to E. coli XL-I Blue strain.
- the cells were detached by trypsin treatment, and after counting the number of cells, 500,000 cells were added with 10% dialyzed fetal serum containing lOOmL of 0.8mgZmL of G418 Iscove's Modified Dalbecco's Medium medium After diluting in 10 wells of 96-well microtiter plates (960 uels), incubate at 37 ° C for 5 weeks in the presence of 5% carbon dioxide, and subculture the viable cells in 197 uels in 1 mL of 0.8 mgZmL.
- Example 7 Assay of HI H-type collagen production using pNOW—hColIal and pNOW—hColIa2 transduced cell clones The production amount was assayed by SDS polyacrylamide electrophoresis. 12.5 L of the culture supernatant and an equal volume of Tris SDS jS-ME sample treatment solution (Daiichi Kagaku) were mixed and heat-treated at 95 ° C for 5 minutes. This was layered on SDS polyacrylamide gel (PAGEL, ATTO) and developed by electrophoresis. After completion of electrophoresis, the polyacrylamide gel was treated with Coomassie Brilliant Blue stain (Amersham Bioscience) to detect and quantify human type I collagen in the polyacrylamide gel. As a comparative control, human type 1 collagen (Cosmova) having a concentration of 12.5 to 100 8 .11 was treated in the same manner and used.
- Tris SDS jS-ME sample treatment solution Tris SDS jS-ME sample treatment solution (Dai
- Cell clones producing large amounts of human type I collagen obtained by gene amplification become 1 X 10 6 cells / mL in a 25 cm 2 culture flask using cell culture medium IS CHO-CD (IS Japan) It was prepared as follows. This was cultured at 37 ° C for 96 hours in the presence of 5% carbon dioxide gas, and then the culture solution was collected, and the cells were removed by centrifugation to obtain a culture supernatant. The culture supernatant (12.5 ⁇ L) and an equal volume of Tris SDS ⁇ ME sample treatment solution (Daiichi Kagaku) were mixed and heat-treated at 95 ° C. for 5 minutes. This was layered on SDS polyacrylamide gel (PAGEL, ATTO) and developed by electrophoresis.
- SDS polyacrylamide gel PAGEL, ATTO
- Fig. 5 shows the results of SDS polyacrylamide gel electrophoresis analysis of the culture supernatant obtained from human type I collagen-producing cell clones.
- polypeptide at the position of 150 kDa, 170 kDa which is considered to be a recombinant H type 1 collagen chain, and a recombinant human type I collagen ⁇ 2 chain.
- Polypeptides at positions of 130 kDa and 150 kDa were detected.
- Example 10 Degradation of recombinant human collagen type I in culture supernatant by pepsin and analysis by SDS-polyacrylamide gel electrophoresis
- Pepsin degradation of the culture supernatant obtained from human type I collagen-producing cell clones was performed by adding 99.7% acetic acid to the culture supernatant to a final concentration of 0.5M and adding pepsin (Sigma) to the final concentration 24 After adding to unit ZmL, it was carried out at 20 ° C for 2 hours. The following pepsin degradation was carried out in the same manner. Samples obtained by pepsin degradation were analyzed by SDS-polyacrylamide gel electrophoresis. As a comparative control, 185 ⁇ g ZmL of commercially available recombinant human collagen type I (Betaton Dickinson) was used.
- Figure 6 shows the results of SDS-polyacrylamide gel electrophoresis analysis of pepsin degradation products.
- the recombinant H-type collagen in the culture supernatant is a polypeptide at the position of 130 kDa considered to be a 1 chain and 120 kDa considered to be a 2 chain in the same manner as commercially available human type I atelocollagen. It was detected as a polypeptide at position. This indicates that the culture supernatant obtained from a human type I collagen-producing cell clone contains recombinant human type I collagen having pepsin resistance substantially equivalent to that of the natural type. It was.
- the polyacrylamide gel was immersed in a transfer buffer, and human type I collagen in the polyacrylamide gel was transferred to a PVDF membrane according to a conventional method.
- an anti-human type I collagen ex 1 chain antibody at a concentration of 2 g / mL was reacted with a horseradish peroxidase (HRP) -labeled anti-goat IgG antibody.
- HRP horseradish peroxidase
- a comparative control 50 gZmL of recombinant human type I collagen (Betaton Dickinson) was used. Detection of human type I collagen ⁇ 2 chain was carried out using an antihuman type I collagen ⁇ 2 chain antibody instead of the antihuman type I collagen ⁇ 1 chain antibody. As a comparative control, 10 gZmL human type I collagen was used.
- Fig. 7 shows the results of Western blot analysis.
- the purified collagen solution finally obtained in lOOmL of the original culture supernatant was concentrated to about 300 ⁇ L and electrophoresed by SDS-PAGE to confirm the purity.
- Human type II collagen production test gene transfer of human type 1 collagen with expression vector pNOW—hColIIal and establishment of G418 resistant initial clone
- 1 ⁇ g of pNOW—hColIIal was introduced into 1.5 million CHO cells, strain DG44, in a 25 cm 2 culture flask using the lipofectin method. The introduction method followed the manufacturer's instructions. 48 hours later, the cells were detached by trypsin treatment, and after counting the number of cells, 500,000 cells were added with 10% dialyzed fetal serum containing lOOmL of 0.8mgZmL of G418.
- Isc After dilution with ove's Modified Dalbecco's Medium medium, seed in 10 96-well microtiter plates (960 uels), incubate at 37 ° C for about 3 weeks in the presence of 5% CO2, 126 uels The viable cells in the medium were transferred to a 24-well plate with Iscove's Modified Dalbecco's Medium medium supplemented with 10% dialyzed fetal serum containing ImL of 0.8mgZmL of G418 and cultured until confluent. After discarding the culture supernatant, 1 mL of PBS (manufactured by Invitrogen) was added to each well, and the culture supernatant was discarded again.
- PBS manufactured by Invitrogen
- CHO cell-free serum-free medium cell CD medium ProCH04 (Takara Bio Inc.) was added and cultured in the presence of 5% carbon dioxide at 37 ° C for 96 hours. Subsequently, the production amount of human type II collagen in the culture supernatant was examined.
- the production amount was assayed by SDS-polyacrylamide electrophoresis.
- 7.5 ⁇ L of the culture supernatant and an equal volume of Tris SDS ⁇ -ME sample treatment solution (Daiichi Chemical Co., Ltd.) were mixed and heat-treated at 95 ° C. for 5 minutes. This was layered on SDS-polyacrylamide gel (PAGEL, ATTO) and developed by electrophoresis. After electrophoresis, the polyacrylamide gel was treated with Coomassie Brilliant Blue staining solution (Amersham Biosciences) to detect and quantify human type II collagen in the polyacrylamide gel.
- human type II collagen Cosmo Bio
- clones with the highest human type II collagen production were subcultured and stabilized, and then gene amplification with MTX was performed. Initially 1 week in medium containing 5 nM MTX, 1 week in medium containing 25 nM MTX, 1 week in medium containing 50 nM MTX, 3 weeks in medium containing 250 nM MTX, medium containing 1 M MTX After further amplification for 3 weeks, the level of human type II collagen production increased to gZmL (4 days) per medium at 25 nM MTX.
- the concentration of MTX used for gene amplification is generally multi-step between ⁇ and L0 ⁇ ⁇ , and 10 ⁇ is often used as the final concentration.
- Cell clones producing a large amount of human type II collagen obtained by gene amplification become 1 X 10 6 cells / mL in a 25 cm 2 culture flask using cell culture medium IS CHO-CD (IS Japan) It was prepared as follows. This was cultured at 37 ° C for 96 hours in the presence of 5% carbon dioxide gas, and then the culture solution was collected, and the cells were removed by centrifugation to obtain a culture supernatant. 7.5 ⁇ L of the culture supernatant and an equal volume of Tris SDS ⁇ -ME sample treatment solution (Daiichi Kagaku) were mixed and heat-treated at 95 ° C. for 5 minutes.
- SDS-polyacrylamide gel PAGEL, ATTO
- SDS-polyacrylamide gel electrophoresis was carried out in the same manner. After the electrophoresis was completed, the polyacrylamide gel was treated with Kumashi Precious Blue Staining Solution (Amersham Biosciences) to detect human type II collagen in the polyatarylamide gel. As a comparative control, human type II collagen (Cosmono) having a concentration of 100 / z gZ mL was similarly treated.
- Fig. 8 shows the results of SDS-polyacrylamide gel electrophoresis analysis of culture supernatants obtained from human type IV collagen-producing cell clones. Polypeptides at 170 kDa and 200 kDa, which are considered to be recombinant HI type collagen, were detected in the culture supernatant.
- Example 17 Analysis of recombinant human type II collagen in culture supernatant by Western blotting
- the polyacrylamide gel was immersed in a transfer buffer, and human type II collagen in the polyacrylamide gel was transferred to a PVDF membrane according to a conventional method.
- an anti-human type II collagen chain antibody (Cosmono) at a concentration of 1 ⁇ g / mL was reacted with a horseradish superoxidase (HRP) -labeled anti-rabbit IgG antibody.
- HRP horseradish superoxidase
- Example 18 Decomposition of recombinant human collagen type II in culture supernatant by pepsin and analysis by SDS-polyacrylamide gel electrophoresis and Western blotting
- Example 19 Production test of human type III collagen.
- Expression vector pNOW gene transfer of human type III collagen with hColIIIal and establishment of G418 resistant initial clone
- CHO cells in a 25 cm 2 culture flask were transfected into the DG44 strain using the lipofectin method. The introduction method followed the manufacturer's instructions. After 48 hours, the cells were detached by trypsin treatment, and after counting the number of cells, 300,000 cells were added to Iscove's Modified Dalbecco's Medium medium supplemented with 10% dialyzed fetal blood serum containing lOOmL 0.8mgZmL G418. After dilution, the cells were plated in 10 96-well microtiter plates (960 uels) and cultured at 37 ° C in the presence of 5% carbon dioxide for approximately 3 weeks. (G418 resistant strain).
- Viable cells were transferred to a 24 well plate with Iscove's Modified Dalbecco's Medium medium supplemented with 10% dialyzed fetal serum containing ImL of 0.8 mg / mL G418 and cultured until confluent. After discarding the culture supernatant, PBS (Invitrogen) ImL was added to each well, and the culture supernatant was again discarded. Add 0.5mL serum-free medium for CHO cells. CHO- S- SFM Saga (Invitrogen) was added and cultured in the presence of 5% carbon dioxide at 37 ° C for 72 hours. Subsequently, the production amount of human type III collagen in the culture supernatant was examined.
- Iscove's Modified Dalbecco's Medium medium supplemented with 10% dialyzed fetal serum containing ImL of 0.8 mg / mL G418 and cultured until confluent. After discarding the culture supernatant, PBS (Invitrogen) ImL was added to
- the production amount was tested by the dot plot method. Cultured for 72 hours on nylon membrane 1 ⁇ L of supernatant and commercially available human type III collagen (Betaton's Dickinson) in serum-free medium for CHO cells CHO-S-SFM II 2-fold dilution series (0.125 to 8 gZmL) ) And CHO-S-SFM II each with 1 ⁇ L, air-dried for 1 hour, blocked with Block Ace, and then blocked with anti-human type III collagen antibody (Cosmono) at a concentration of 1 ⁇ g ZmL. HRP-labeled anti-rabbit IgG antibody was reacted. Reacted antibodies were detected using luminocapture with a method of detecting HRP activity with SuperSignal West Pico reagent o
- clones with the highest human type III collagen production were subcultured and stabilized, and then gene amplification with MTX was performed. First, it was amplified for 2 weeks in a medium containing 15 nM MTX, 2 weeks in a medium containing 60 nM MTX, 2 weeks in a medium containing 250 nM MTX, and further amplified for 4 weeks in a medium containing 1 ⁇ M MTX.
- the production level of human type III collagen increased to 225 ⁇ g / mL (3 days) per medium.
- Example 22 SDS-polyacrylamide gel electrophoresis analysis of recombinant human type III collagen in culture supernatant
- Cell clones producing a large amount of human type III collagen obtained by gene amplification become 1 X 10 6 cells / mL in a 25 cm 2 culture flask using cell culture medium IS CHO-CD (IS Japan) It was prepared as follows. This was cultured for 96 hours at 37 ° C in the presence of 5% carbon dioxide gas, and then the culture solution was collected, and the cells were removed by centrifugation to obtain a culture supernatant. 6 ⁇ L of the culture supernatant and an equal volume of Tris SDS ⁇ -ME sample treatment solution (Daiichi Chemical Co., Ltd.) were mixed and heat-treated at 95 ° C. for 5 minutes.
- SDS-polyacrylamide gel PAGEL, ATTO
- SDS-polyacrylamide gel electrophoresis was carried out in the same manner. After completion of electrophoresis, remove polyacrylamide gel. Human III type collagen was detected in polyatyramide gel by treatment with Liant Blue staining solution (Amersham Biosciences). As a comparative control, human type III collagen (Betaton's Dickinson) at a concentration of 100 ZmL was similarly treated.
- Fig. 12 shows the results of SDS-polyacrylamide gel electrophoresis analysis of culture supernatants obtained from human type III collagen-producing cell clones. Polypeptides at 140 kDa and 170 kDa, which are considered to be recombinant rabbit collagens, were detected in the culture supernatant.
- the polyacrylamide gel was immersed in a transfer buffer, and human type III collagen in the polyacrylamide gel was transferred to a PVDF membrane according to a conventional method.
- Block Ace react with anti-human type III collagen chain antibody (Cosmo Bio) at a concentration of 1 ⁇ g / mL, followed by a bow I and anti-rabbit IgG antibody labeled with horseradish superoxidase (HRP). I let you.
- the reacted antibody was detected using a TMB peroxidase reagent (Funakoshi Co., Ltd.) by a method for detecting HRP activity.
- the production method of the present invention can be applied not only to collagen but also to proteins such as collectin having a triple helical structure.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020077024903A KR101304735B1 (ko) | 2005-03-31 | 2006-03-31 | 3중 나선구조를 갖는 단백질의 제조방법 |
CN2006800149518A CN101171334B (zh) | 2005-03-31 | 2006-03-31 | 具有三螺旋结构的蛋白质的生产方法,生产所述蛋白的cho细胞和试剂盒 |
DK06730889.0T DK1870460T3 (da) | 2005-03-31 | 2006-03-31 | Fremgangsmåder til fremstilling af proteiner med tripelhelixstruktur |
AU2006231795A AU2006231795B9 (en) | 2005-03-31 | 2006-03-31 | Process for production of protein having triple-helical structure |
ES06730889T ES2387467T3 (es) | 2005-03-31 | 2006-03-31 | Procedimientos de producción de proteínas que tienen estructura helicoidal triple |
JP2007511203A JP4892474B2 (ja) | 2005-03-31 | 2006-03-31 | 3重螺旋構造を有するタンパク質の製造方法 |
US11/909,873 US9018354B2 (en) | 2005-03-31 | 2006-03-31 | Methods of producing proteins having triple-helix structure |
CA2602611A CA2602611C (en) | 2005-03-31 | 2006-03-31 | Methods of producing proteins having triple-helix structure |
EP06730889A EP1870460B9 (en) | 2005-03-31 | 2006-03-31 | Methods of producing proteins having triple-helix structure |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-102999 | 2005-03-31 | ||
JP2005102999 | 2005-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006106970A1 true WO2006106970A1 (ja) | 2006-10-12 |
Family
ID=37073520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/306941 WO2006106970A1 (ja) | 2005-03-31 | 2006-03-31 | 3重螺旋構造を有するタンパク質の製造方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US9018354B2 (ja) |
EP (3) | EP2383338B1 (ja) |
JP (1) | JP4892474B2 (ja) |
KR (1) | KR101304735B1 (ja) |
CN (1) | CN101171334B (ja) |
AU (1) | AU2006231795B9 (ja) |
CA (1) | CA2602611C (ja) |
DK (2) | DK2390326T3 (ja) |
ES (2) | ES2489715T3 (ja) |
HK (1) | HK1164917A1 (ja) |
PT (2) | PT2390326E (ja) |
WO (1) | WO2006106970A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010074081A1 (ja) | 2008-12-22 | 2010-07-01 | 国立大学法人北海道大学 | 三重螺旋構造を有するタンパク質、およびその製造方法 |
WO2010074080A1 (ja) * | 2008-12-22 | 2010-07-01 | 国立大学法人北海道大学 | 動物細胞を用いて外来遺伝子由来タンパク質を大量に生産するための発現ベクター、およびその利用 |
JP2011130725A (ja) * | 2009-12-25 | 2011-07-07 | Contig I:Kk | Lnaオリゴヌクレオチドとそれを含有する化粧品 |
CN114920826A (zh) * | 2022-06-15 | 2022-08-19 | 江南大学 | Ⅲ型类人胶原蛋白及其编码基因、表达载体和重组酵母菌 |
CN118255874A (zh) * | 2024-05-31 | 2024-06-28 | 北京鑫康辰医学科技发展有限公司 | 一种天然活性胶原蛋白及其制备方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2997083B1 (fr) | 2012-10-19 | 2014-12-12 | Nvh Medicinal | Proteines recombinantes derivees du collagene a activite de liaison au facteur willebrand |
US10373702B2 (en) * | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
CN111087478B (zh) * | 2020-01-10 | 2022-04-05 | 杭州嘉颜生物医药科技有限公司 | 一种重组胶原蛋白及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07501939A (ja) * | 1991-10-23 | 1995-03-02 | トーマス・ジェファーソン・ユニバーシティ | 組み換えdna合成システムにおけるヒトプロコラーゲン及びコラーゲンの合成 |
JP2000508544A (ja) * | 1996-04-12 | 2000-07-11 | ファイブローゲン,インコーポレーテッド | 組換えdna系におけるヒトプロコラーゲンおよびコラーゲンの合成 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01107857A (ja) | 1987-10-21 | 1989-04-25 | Mitsubishi Electric Corp | 超電導物質の分離方法 |
US20020142391A1 (en) * | 1991-06-12 | 2002-10-03 | Kivirikko Kari I. | Synthesis of human procollagens and collagens in recombinant DNA systems |
US5593859A (en) | 1991-10-23 | 1997-01-14 | Thomas Jefferson University | Synthesis of human procollagens and collagens in recombinant DNA systems |
US20020098578A1 (en) * | 1992-10-22 | 2002-07-25 | Darwin J. Prockop | Synthesis of human procollagens and collagens in recombinant dna systems |
JPH0823979A (ja) | 1994-07-15 | 1996-01-30 | Terumo Corp | ヒト・コラーゲン発現ベクターおよびヒト・コラーゲンの製造方法 |
JP3582965B2 (ja) | 1996-08-23 | 2004-10-27 | 株式会社イムノ・ジャパン | 哺乳動物細胞用発現ベクター |
JPH11178574A (ja) | 1997-12-22 | 1999-07-06 | Toyota Central Res & Dev Lab Inc | 新規コラーゲン様タンパク質 |
JP2002325584A (ja) | 2000-11-30 | 2002-11-12 | Japan Science & Technology Corp | 組換えヒトiv型コラーゲンペプチドとその製造方法 |
JP2004016144A (ja) | 2002-06-18 | 2004-01-22 | Japan Science & Technology Corp | ヒト・コラーゲンを産生する形質転換カイコ |
-
2006
- 2006-03-31 EP EP11002042.7A patent/EP2383338B1/en not_active Not-in-force
- 2006-03-31 AU AU2006231795A patent/AU2006231795B9/en not_active Ceased
- 2006-03-31 PT PT110020484T patent/PT2390326E/pt unknown
- 2006-03-31 JP JP2007511203A patent/JP4892474B2/ja not_active Expired - Fee Related
- 2006-03-31 CN CN2006800149518A patent/CN101171334B/zh not_active Expired - Fee Related
- 2006-03-31 DK DK11002048.4T patent/DK2390326T3/da active
- 2006-03-31 WO PCT/JP2006/306941 patent/WO2006106970A1/ja active Application Filing
- 2006-03-31 EP EP11002048.4A patent/EP2390326B1/en not_active Not-in-force
- 2006-03-31 PT PT06730889T patent/PT1870460E/pt unknown
- 2006-03-31 ES ES11002048.4T patent/ES2489715T3/es active Active
- 2006-03-31 US US11/909,873 patent/US9018354B2/en not_active Expired - Fee Related
- 2006-03-31 KR KR1020077024903A patent/KR101304735B1/ko not_active IP Right Cessation
- 2006-03-31 ES ES06730889T patent/ES2387467T3/es active Active
- 2006-03-31 CA CA2602611A patent/CA2602611C/en not_active Expired - Fee Related
- 2006-03-31 DK DK06730889.0T patent/DK1870460T3/da active
- 2006-03-31 EP EP06730889A patent/EP1870460B9/en not_active Not-in-force
-
2012
- 2012-05-29 HK HK12105235.0A patent/HK1164917A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07501939A (ja) * | 1991-10-23 | 1995-03-02 | トーマス・ジェファーソン・ユニバーシティ | 組み換えdna合成システムにおけるヒトプロコラーゲン及びコラーゲンの合成 |
JP2000508544A (ja) * | 1996-04-12 | 2000-07-11 | ファイブローゲン,インコーポレーテッド | 組換えdna系におけるヒトプロコラーゲンおよびコラーゲンの合成 |
Non-Patent Citations (7)
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5645187B2 (ja) * | 2008-12-22 | 2014-12-24 | 国立大学法人北海道大学 | 三重螺旋構造を有するタンパク質、およびその製造方法 |
WO2010074080A1 (ja) * | 2008-12-22 | 2010-07-01 | 国立大学法人北海道大学 | 動物細胞を用いて外来遺伝子由来タンパク質を大量に生産するための発現ベクター、およびその利用 |
KR20110119650A (ko) * | 2008-12-22 | 2011-11-02 | 국립대학법인 홋가이도 다이가쿠 | 3중 나선구조를 갖는 단백질 및 그의 제조방법 |
US8470555B2 (en) | 2008-12-22 | 2013-06-25 | National University Corporation Hokkaido University | Protein substance having triple helix structure and manufacturing method therefor |
AU2009331327B2 (en) * | 2008-12-22 | 2014-04-24 | Fuso Pharmaceutical Industries, Ltd. | Protein substance having triple helix structure and manufacturing method therefor |
WO2010074081A1 (ja) | 2008-12-22 | 2010-07-01 | 国立大学法人北海道大学 | 三重螺旋構造を有するタンパク質、およびその製造方法 |
JP5704753B2 (ja) * | 2008-12-22 | 2015-04-22 | 国立大学法人北海道大学 | 動物細胞を用いて外来遺伝子由来タンパク質を大量に生産するための発現ベクター、およびその利用 |
US9096878B2 (en) | 2008-12-22 | 2015-08-04 | National University Corporation Hokkaido University | Expression vector for producing protein derived from foreign gene in large quantity using animal cells, and use thereof |
KR101686688B1 (ko) | 2008-12-22 | 2016-12-14 | 국립대학법인 홋가이도 다이가쿠 | 3중 나선구조를 갖는 단백질 및 그의 제조방법 |
JP2011130725A (ja) * | 2009-12-25 | 2011-07-07 | Contig I:Kk | Lnaオリゴヌクレオチドとそれを含有する化粧品 |
CN114920826A (zh) * | 2022-06-15 | 2022-08-19 | 江南大学 | Ⅲ型类人胶原蛋白及其编码基因、表达载体和重组酵母菌 |
CN114920826B (zh) * | 2022-06-15 | 2023-04-25 | 江南大学 | Ⅲ型类人胶原蛋白及其编码基因、表达载体和重组酵母菌 |
CN118255874A (zh) * | 2024-05-31 | 2024-06-28 | 北京鑫康辰医学科技发展有限公司 | 一种天然活性胶原蛋白及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2383338A1 (en) | 2011-11-02 |
EP1870460B9 (en) | 2012-12-05 |
EP2383338B1 (en) | 2016-10-19 |
CN101171334B (zh) | 2013-03-27 |
KR101304735B1 (ko) | 2013-09-05 |
DK2390326T3 (da) | 2014-10-13 |
ES2387467T3 (es) | 2012-09-24 |
EP1870460A4 (en) | 2008-12-24 |
CA2602611C (en) | 2015-09-29 |
HK1164917A1 (en) | 2012-09-28 |
AU2006231795B2 (en) | 2012-02-16 |
PT1870460E (pt) | 2012-06-21 |
KR20070121809A (ko) | 2007-12-27 |
EP1870460B1 (en) | 2012-05-30 |
ES2489715T3 (es) | 2014-09-02 |
EP2390326B1 (en) | 2014-07-09 |
EP2390326A1 (en) | 2011-11-30 |
CN101171334A (zh) | 2008-04-30 |
JPWO2006106970A1 (ja) | 2008-09-25 |
DK1870460T3 (da) | 2012-09-03 |
US20120172577A1 (en) | 2012-07-05 |
AU2006231795A1 (en) | 2006-10-12 |
AU2006231795B9 (en) | 2012-04-12 |
US9018354B2 (en) | 2015-04-28 |
JP4892474B2 (ja) | 2012-03-07 |
PT2390326E (pt) | 2014-08-05 |
CA2602611A1 (en) | 2006-10-12 |
EP1870460A1 (en) | 2007-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4892474B2 (ja) | 3重螺旋構造を有するタンパク質の製造方法 | |
EP0873405B1 (en) | Expression augmenting sequence elements (ease) for eukaryotic expression systems | |
JP7402604B2 (ja) | 組換えコラーゲンの水酸化を調節する酵母株及び方法 | |
CN108165593A (zh) | 胶原蛋白7及相关方法 | |
NZ621527A (en) | A genetically modified yeast cell and method of production of recombinant protein or polypeptide thereof | |
US8470555B2 (en) | Protein substance having triple helix structure and manufacturing method therefor | |
JPH09512710A (ja) | 組換えフィブリン鎖、フィブリンおよびフィブリン−ホモログ | |
WO2010071938A1 (en) | Novel collagen constructs | |
JP6000130B2 (ja) | 新規なシグナルペプチドおよび組換えタンパク質の生成のためのその使用 | |
JP4701336B2 (ja) | ヒト・コラーゲンを産生する形質転換カイコ | |
JP2008125367A (ja) | 組換えプロリン水酸化ヒトコラーゲンを生産する組換え細胞およびトランスジェニック生物 | |
AU663216B2 (en) | Bone-related cadherin-like protein and process for its production | |
AU2012200573B2 (en) | "Process for production of protein having triple-helical structure" | |
WO2008044794A1 (fr) | Réactif auxiliaire pour tranfert de gène | |
JP2008503233A (ja) | 胎盤および下垂体アイソフォームに由来するキメラヒト成長ホルモンおよび該キメラを得るための方法 | |
JP2001161214A (ja) | 形質転換カイコ | |
KR20070035483A (ko) | 태반 및 뇌하수체 아형 유래의 키메라 인간 성장 호르몬 및상기 키메라의 제조 방법 | |
JP2009537151A (ja) | ヒトoct−2変異体ペプチド鎖、核酸、および方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680014951.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007511203 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006231795 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2602611 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006231795 Country of ref document: AU Date of ref document: 20060331 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006231795 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006730889 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077024903 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006730889 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11909873 Country of ref document: US |